Range Cancer Therapeutics ETFRange Cancer Therapeutics ETFRange Cancer Therapeutics ETF

Range Cancer Therapeutics ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪9.70 M‬USD
Fund flows (1Y)
‪−2.67 M‬USD
Dividend yield (indicated)
Discount/Premium to NAV
0.1%
Shares outstanding
‪780.81 K‬
Expense ratio
0.79%

About Range Cancer Therapeutics ETF


Issuer
Cottonwood ETF Holdings LLC
Brand
Range
Inception date
Oct 13, 2015
Structure
Open-Ended Fund
Index tracked
Range Oncology Therapeutics Index
Replication method
Physical
Management style
Passive
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
Primary advisor
Exchange Traded Concepts LLC
Distributor
Quasar Distributors LLC
CNCR takes an approach to niche coverage within the healthcare sector. It provides equal-weighted exposure to companies that generate their revenue from oncology products or are in constant development and production of cancer therapeutic medicine. Cancer Therapeutics is a term used to refer to the wide range of treatments and interventions used to treat various kinds of cancer. Equal weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space. Prior to June 20, 2023, the fund tracked the Loncar Cancer Immunotherapy Index and traded under the name Loncar Cancer Immunotherapy ETF. Effective October 20, 2023, the Loncar China BioPharma ETF that traded under the symbol CHNA merged into CNCR, acquiring its assets and expanding the funds exposure to China. Before June 3, 2024, the fund's index name swapped Cancer for Oncology, keeping the strategy unchanged.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharma, biotech & life sciences
Strategy
Equal
Geography
Global
Weighting scheme
Equal
Selection criteria
Market cap

Returns


1 month3 monthsYear to date1 year3 years5 years
Price performance
NAV total return

What's in the fund


As of January 30, 2025
Exposure type
StocksBonds, Cash & Other
Health Technology
Stocks99.34%
Health Technology92.50%
Health Services3.62%
Technology Services2.07%
Finance1.05%
Bonds, Cash & Other0.66%
Mutual fund0.76%
Cash−0.10%
Stock breakdown by region
100%
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings

Dividends


Dividend payout history

Assets under management (AUM)



Fund Flows